Literature DB >> 32248855

Core principles for infection prevention in hemodialysis centers during the COVID-19 pandemic.

Gang Chen1, Yangzhong Zhou2, Lei Zhang1, Ying Wang1, Rong-Rong Hu1, Xue Zhao1, Dan Song1, Jing-Hua Xia1, Yan Qin1, Li-Meng Chen1, Xue-Mei Li1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32248855      PMCID: PMC7163189          DOI: 10.1017/ice.2020.109

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


× No keyword cloud information.
To the Editor—The COVID-19 outbreak began at the end of December 2019, and >600,000 confirmed cases had been reported worldwide by the end of March 2020. The World Health Organization declared a global pandemic.[1] Nosocomial transmission was severe in some locations, and the burden to the health system was extreme.[2] Hemodialysis centers, which generally serve high volumes of highly mobile dialysis patients, have an exceptionally high risk of exposure during this outbreak period. In a general tertiary-care hospital, dialysis centers routinely accept patients from outpatient clinics and emergency rooms, further adding to the difficulty of preventing nosocomial infection.[3] Dialysis patients, commonly regarded as immune compromised, are likely to develop severe illness as a result of close contact in a medical unit. Droplet spread and close contact are the main routes of COVID-19 transmission.[4] Thus, the hemodialysis center in our hospital implemented multiple strategies for infection prevention, including area management and integrated symptom monitoring, in the context of this pandemic. Based on various levels of exposure to the mobile population, our hospital environments were classified as low-risk, medium-risk, high-risk, and extremely high-risk, and the dialysis center belongs to the high-risk category. We avoid moving across the area by designing a specific walking route for our patients entering the hemodialysis center. Medical staff wears personal protective equipment (PPE) when inter-area contact is inevitable. For example, N95 masks and protective glasses are required when entering the fever clinic. We advise the use of hand sanitizer whenever staff return to the hemodialysis center. In the dialysis center, a 1-way route is followed by our patients, and mask-wearing and hand sanitizing by the patients are ensured. During the dialysis session, we provide necessary education on maintaining social distancing and self-protection. Between the 2 dialysis shifts, we strictly leave at least 30 minutes for environmental and air disinfection, and we utilize a chlorine-containing disinfectant to clean our dialysis facilities.[6-8] We monitor and respond to our regular patients’ symptoms in an integrated way. Between the dialysis sessions, we strictly record the body temperatures and any suspicious respiratory symptoms of our patients. For patients referred from other departments in the hospital, we collect records of their contact history, temperature, and potential warning symptoms before admission. Based on this information, all of our patients are classified into 3 categories (Table 1). A negative SARS-CoV-2 swab test is needed for patients in category C before their dialysis session can be scheduled. In emergency cases, we perform continuous renal replacement therapy (CRRT) in a separate place, preferably in a negative-pressure ward, before completely ruling out COVID-19 for these patients.[5,6] Notably, patients with a positive swab test are sent to designated hospitals for further treatment.
Table 1.

High-Risk and Suspicious Patient Identification and Classification Management

CategoryDefinitionManagement
A: Temperature warningTemperature 37.0~37.2°C in the past 14 d, without other symptomsClose observation
B: Symptom warningSuspicious symptoms (ie, sore throat, cough, and diarrhea, etc) in the past 14 d; but the temperature within the normal rangeSeparate dialysis and close observation
C: High-risk warningTemperature >37.3°C within 14 d, together with suspicious history, or respiratory symptoms, or chest imaging abnormalitiesScreen SARS-CoV-2 swab; send positive patients to the specific hospitals; arrange negative patients for separate dialysis and close observation
High-Risk and Suspicious Patient Identification and Classification Management Medical staff are strictly required to maintain hand hygiene and to wear a mask at work. N95 masks and protective goggles are used when operating CRRT for patients in category C. The equipment used is disinfected between patients, and medical waste is packed and labeled separately to avoid potential contamination.[7] The waste liquid generated during CRRT is discharged according to the requirements of the medical wastewater discharge standards.[8] In addition to the strategies summarized above, we promote work–life balance for staff and encourage patients to take the initiative to participate. Our hemodialysis center has strived to achieve zero infection during the ongoing COVID-19 outbreak.
  3 in total

1.  Covid-19: WHO declares pandemic because of "alarming levels" of spread, severity, and inaction.

Authors:  Elisabeth Mahase
Journal:  BMJ       Date:  2020-03-12

2.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

Review 3.  Infection control in hemodialysis units: a quick access to essential elements.

Authors:  Ayman Karkar; Betty Mandin Bouhaha; Mienalyn Lim Dammang
Journal:  Saudi J Kidney Dis Transpl       Date:  2014-05
  3 in total
  1 in total

Review 1.  The frail world of haemodialysis patients in the COVID-19 pandemic era: a systematic scoping review.

Authors:  Gaetano Alfano; Annachiara Ferrari; Riccardo Magistroni; Francesco Fontana; Gianni Cappelli; Carlo Basile
Journal:  J Nephrol       Date:  2021-08-21       Impact factor: 3.902

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.